Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab Master Protocol Continuation Study in Japan
jRCT2031210487Active, not recruiting
- Sponsor
- Pfizer
- Start
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Open-label trial of avelumab in cancer, Nonhematologic neoplasms and hematopoietic malignancies (8 arms), sponsored by Pfizer. Primary endpoints: Adverse events leading to permanent discontinuation of study intervention and Serious adverse events. Started Sep 2021; status: active, not recruiting.
02
Drugs
avelumab
03
Conditions
cancerNonhematologic neoplasmshematopoietic malignancies
Beyond the preview
Go deeper on jRCT2031210487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210487.